Examining how Guselkumab affects immune cells in scalp psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of Guselkumab, an FDA-approved medication for psoriasis, on immune cells in scalp psoriasis lesions. It is a one-arm, open-label study involving ten subjects with moderate to severe scalp psoriasis. Participants will undergo biopsy procedures to collect samples for molecular profiling, which will help correlate immune cell profiles with treatment responses to Guselkumab. The goal is to better understand the immune spatial features associated with the drug's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive

   \-

Where it's running

• University of California San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Raymond Cho, MD, PhD — University of California, San Francisco
• Study coordinator: Jeffrey Cheng, MD, PhD
• Email: rashes@ucsf.edu
• Phone: 415 575 0524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• Colonic delivery of two antibodies to see if they reach the bloodstream in healthy people

  This early study tests whether guselkumab and adalimumab given directly into the colon can enter the body in healthy adults.

  Recruiting Phase 1 Surmount Services, Inc. · Maroochydore, Queensland · NCT07788807

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Guselkumab in Moderate-to-Severe Ulcerative Colitis: Real-World Experience

  This real-world study tests whether guselkumab helps adults with moderate-to-severe ulcerative colitis and how safe it is for them.

  Recruiting Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07726888

• Guselkumab in Crohn's Disease: Optimising Care for Real-World Patients (OPTIM Study A)

  This study tests whether guselkumab can help adults with Crohn's disease, including those who have had prior therapies or partial responses, when used in real-world clinical settings.

  Recruiting Phase 4 Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Amiens · NCT07616687

• Guselkumab use in Crohn's disease and ulcerative colitis

  This study looks at how long people with moderate-to-severe Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen-Cilag Pharma GmbH · Vienna · NCT07606339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.